(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of -24.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 118.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.42%.
Cytomx Therapeutics's revenue in 2026 is $113,631,000.On average, 11 Wall Street analysts forecast CTMX's revenue for 2026 to be $5,361,444,204, with the lowest CTMX revenue forecast at $664,186,748, and the highest CTMX revenue forecast at $14,232,573,180. On average, 9 Wall Street analysts forecast CTMX's revenue for 2027 to be $6,263,687,682, with the lowest CTMX revenue forecast at $0, and the highest CTMX revenue forecast at $15,068,736,854.
In 2028, CTMX is forecast to generate $8,452,454,115 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $15,068,736,854.